Cancer-Focused Biotech's Shares Soar After Upsized IPO
Swiss oncology firm ADC Therapeutics SA saw a strong debut Friday on the New York Stock Exchange, with shares closing more than 50% above its already upsized initial public offering price...To view the full article, register now.
Already a subscriber? Click here to view full article